Unlike conventional antiretroviral drugs, treatment with broadly neutralizing antibodies does not rely on vigilant daily dosing and could potentially reduce the body’s reservoir of latent viruses.
A new study reveals how the drug fidaxomicin selectively targets a dangerous pathogen without causing harm to beneficial bacteria. The findings could inform the development of new narrow-spectrum antibiotics for treating other types of infection.
In studying how bacteria respond to viral infection, scientists are learning that their defense strategies cooperate in ways reminiscent of the elaborate immune systems of animals.
FMRP, a protein whose loss causes intellectual disability, may regulate a neuron's synaptic response by establishing a feedback loop between the cell's nucleus and its faraway dendrites.
Protein folding diseases, from Alzheimer's to Gaucher's, may one day be treated by a unique class of protein corrector molecules that are already helping manage cystic fibrosis.
The findings, which may have implications for a wide range of human diseases, suggest that nuclear pore complexes vary in structure and function even within a single nucleus.
Increasingly, hospitalized patients contract infections that evade current antibiotics including colistin, long used as a last treatment option. The discovery of a new colistin variant might make it possible to outmaneuver these pathogens.
This year's scientific endeavors included multiple attacks on SARS-CoV-2—and a lot more. Here are the most memorable science stories to come out of Rockefeller labs in 2021, from the benefits of brown fat to the pitfalls of modern IVF screening techniques.
Researchers found that the antibodies present in people who have had COVID or taken two doses of mRNA vaccine are inadequate against Omicron. But their protective ability increases significantly after a booster dose.
